Quantcast
Last updated on April 16, 2014 at 1:21 EDT

Latest Abbott Stories

2013-09-12 16:27:10

ABBOTT PARK, Ill., Sept. 12, 2013 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 14 cents per share. This marks the 359(th) consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable Nov. 15, 2013, to shareholders of record at the close of business on Oct. 15, 2013. Abbott has increased its dividend payout for 41 consecutive years and is a member of the S&P 500 Dividend...

2013-09-12 12:29:34

- Abbott Secured Highest Overall Score in its Industry Sector, More Than Doubling the Average Industry Score ABBOTT PARK, Ill., Sept. 12, 2013 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that it was named an Industry Group Leader in the 2013 Dow Jones Sustainability Index (DJSI), one of the most prestigious benchmarks for worldwide corporate sustainability. As the leader in the Health Care Equipment & Services industry group, Abbott was one of only 24 companies...

2013-09-12 04:20:25

THE HAGUE, The Netherlands, September 12, 2013 /PRNewswire/ -- Royal Dutch Shell plc (NYSE:RDS.A) (NYSE:RDS.B) (the 'Company') today announces the appointment of John Abbott as Downstream Director with effect from October 1, 2013. In his new role, Mr Abbott will become a member of the Company's Executive Committee and will take over from Ben van Beurden who, as previously announced, becomes Chief Executive Officer with effect from January 1, 2014. Notes for Editors...

2013-08-21 08:26:53

ABBOTT PARK, Ill., Aug. 21, 2013 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that it has completed its acquisition of IDEV Technologies, a privately held company focused on developing next-generation medical devices for use by interventional radiologists, vascular surgeons and interventional cardiologists. The acquisition expands Abbott's global peripheral technology portfolio with IDEV Technologies' SUPERA Veritas(®) self-expanding nitinol stent system. SUPERA Veritas...

2013-08-19 12:24:39

ABBOTT PARK, Ill., Aug. 19, 2013 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that it has completed its acquisition of OptiMedica Corporation, a privately-held, Silicon Valley-based ophthalmic device company. The acquisition expands Abbott's vision care business into the femtosecond laser-assisted cataract surgery market. Most cataract procedures are performed manually with the surgeon making incisions into the eye by hand. OptiMedica's Catalys(® )Precision Laser System is...

2013-08-15 08:26:51

ABBOTT PARK, Ill., Aug. 15, 2013 /PRNewswire/ -- Blood transfusion is a life-saving treatment that helps save millions of lives every year. The need for blood is great: Approximately every two seconds, someone in the United States (U.S.) requires a blood transfusion.(1,2 )However, despite nearly 40 percent of the U.S. population being eligible to donate blood, less than 10 percent does so annually.(3) Often this means that hospitals and clinics face the challenge of providing enough...

2013-07-31 23:29:30

Abbott's Fire and Flood Restoration announces that they have recently been named an accredited member of the the Denver Better Business Bureau. Abbott's is pleased to be recognized for their commitment to superior customer service and customer satisfaction. Denver, CO (PRWEB) July 31, 2013 Abbott’s Fire and Flood Restoration announces that they have recently been named an accredited member of the the Denver Better Business Bureau. Abbott's is pleased to be recognized for...

2013-07-29 16:26:01

CAMBRIDGE, Mass., July 29, 2013 /PRNewswire/ -- IntelligentMDx (privately held) announced today that the U.S. Food and Drug Administration (FDA) has cleared its automated molecular diagnostic test that detects the presence of vanA and vanB genes that can be associated with vancomycin-resistant enterococci (VRE). This is one of the tests in IMDx's portfolio of infectious disease products to be cleared by the FDA for use on Abbott's fully automated m2000 platform. VRE are bacteria...

2013-07-25 12:27:21

Only inpatient blood glucose monitoring system among leading hospital brands to use individually foil-wrapped test strips, helping reduce risk of test strip cross-contamination ABBOTT PARK, Ill., July 25, 2013 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that it has received U.S. Food and Drug Administration (FDA) clearance for its FreeStyle Precision Pro Blood Glucose and Beta-Ketone Monitoring System(TM), an advanced blood glucose monitoring system designed to address the key...

2013-07-15 08:27:30

ABBOTT PARK, Ill., July 15, 2013 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it has entered into an agreement to purchase OptiMedica Corporation, a privately held, Silicon Valley-based ophthalmic device company. The acquisition will enable Abbott to expand its vision care business into the femtosecond laser-assisted cataract surgery market. Under the terms of the agreement, Abbott will acquire OptiMedica for $250 million, net of cash, plus additional payments totaling up to...